Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Reporting Date: March 31, 2026
Shuttle Pharmaceuticals underwent a strategic pivot in late 2025. On November 20, 2025, the Company committed to winding down clinical trials for its lead product candidate, Ropidoxuridine. Concurrently, on November 21, 2025, the Company acquired substantially all assets of Molecule.ai, an AI-driven platform for molecular discovery and early-stage drug development. The Company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11.72) million | $(9.14) million |
| Operating Expenses | $11.92 million | $7.70 million |
| Research & Development | $4.05 million | $3.62 million |
| General & Administrative | $5.67 million | $1.39 million |
| Cash and Cash Equivalents (Year End) | $0.33 million | $1.92 million |
| Working Capital Deficit | $(7.46) million | $0.68 million (Surplus) |
| Stockholders' Equity | $2.25 million | $0.71 million |
Debt and Liquidity: As of December 31, 2025, the Company had no outstanding principal on related party notes or convertible bridge notes (converted to equity in 2025). However, current liabilities include $4.44 million in consideration payable and $2.0 million in contingent consideration related to the Molecule.ai acquisition. The Company reported a working capital deficit of approximately $7.5 million.
Material Changes vs. Prior Period
- Strategic Shift: Transitioned from clinical-stage biopharma (Ropidoxuridine) to an AI-driven drug discovery platform (Molecule.ai). Clinical trial wind-down costs of approximately $0.8 million were recorded in R&D.
- Expense Surge: General and Administrative (G&A) expenses increased 307% to $5.67 million, primarily driven by $3.5 million in investor relations and marketing costs.
- Acquisition Impact: The Molecule.ai acquisition resulted in $10.12 million in total purchase consideration, creating significant current liabilities ($6.44 million) and a new intangible asset ($9.84 million).
- Capital Structure: The Company executed multiple equity financings in 2025 (March, June, November) and a subsequent public offering in March 2026 to address liquidity. A 1-for-25 reverse stock split was effectuated in June 2025 to maintain Nasdaq listing compliance.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The Company's financial statements include a "substantial doubt" regarding its ability to continue as a going concern. Continued operations depend on raising additional equity or debt financing to fund operations, milestone payments for Molecule.ai, and commercialization efforts.
Outlook: The Company expects to derive future revenue from licensing the Molecule.ai platform. No revenue was generated in 2025. Management plans to use proceeds from the March 2026 offering ($3.36 million net) for marketing and working capital.
Key Risks:
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including segregation of duties and IT general controls. Disclosure controls were deemed ineffective as of December 31, 2025.
- Nasdaq Compliance: The Company faced repeated non-compliance with Nasdaq minimum bid price and stockholders' equity requirements throughout 2025, requiring reverse splits and equity raises to maintain listing.
- Customer Acquisition: The Company currently has no customers for the Molecule.ai platform; future revenue is contingent on acquiring and retaining licensees.
- Legal Proceedings: A dispute with former financial advisor Boustead regarding a Right of First Refusal (ROFR) is ongoing, though no loss is currently deemed probable or estimable.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $3.36 million net proceeds from the March 2026 offering against the $7.5 million working capital deficit and upcoming Molecule.ai milestone payments.
- Internal Control Remediation: Review the timeline and progress of remediation for the identified material weaknesses in financial reporting and IT controls.
- Acquisition Milestones: Confirm the specific technology development milestones required to trigger the $2.0 million contingent consideration for Molecule.ai and the probability of their achievement.
- Revenue Generation: Monitor the Company's ability to secure its first commercial license for the Molecule.ai platform to validate the new business model.
- Related Party Transactions: Scrutinize the $3.5 million paid to IR Agency LLC and the $0.3 million paid to Bowery Consulting Group for value received relative to the Company's financial distress.